Use of epigenetic drugs in disease: an overview

Area of Science:

• Molecular Biology
• Pharmacology
• Genetics

Background:

• Epigenetic alterations like DNA methylation and histone modifications regulate gene expression.
• Dysregulation of these epigenetic events is linked to various diseases, including cancer, cardiovascular, neurological, and metabolic disorders.
• Targeting epigenetic modifications offers a promising therapeutic strategy.

Purpose of the Study:

• To review epigenetic events associated with major human diseases.
• To discuss the development and therapeutic potential of epigenetic drugs.
• To highlight key classes of epigenetic inhibitors.

Main Methods:

• Literature review of epigenetic mechanisms in disease.
• Analysis of current epigenetic drug classes and their targets.
• Discussion of therapeutic applications in cardiovascular, neurological, metabolic disorders, and cancer.

Main Results:

• Specific epigenetic changes are implicated in diverse pathologies.
• Epigenetic drugs, including DNA methylation inhibitors and histone-modifying enzyme inhibitors, show therapeutic promise.
• Bromodomain inhibitors, histone acetyl transferase inhibitors, histone deacetylase inhibitors, and protein methyltransferase inhibitors represent major classes.

Conclusions:

• Understanding disease-specific epigenetic alterations is crucial for developing targeted therapies.
• Epigenetic drugs offer a novel approach to reverse pathological gene expression and treat diseases.
• Further research into epigenetic drug development holds significant clinical potential.